CollPlant - יחס שווי פעילות לרווח לפני ריבית, מסים ופחת CLGN
CollPlant Biotechnologies (CLGN) develops biotechnologies by creating recombinant collagen for aesthetics and 3D tissue printing. This price trend visualization on GURU.Markets shows an EV/EBITDA value of 0.00. This price action reflects the platform's diversification into regenerative therapy and bioprinting. The high business valuation is justified by rhCollagen patents and protein production in tobacco, which ensures exceptional compatibility and pricing power.
collplant.com (CLGN) - פילוחי מדדים ודוחות פיננסיים
To diversify my portfolio with high-quality assets, I utilize EV/EBITDA, which compares the total enterprise value of a business with its operating profit before interest and taxes to determine the price per unit of fundamental income. Given the high value of CollPlant Biotechnologies (CLGN) genetic engineering patents, the current EV/EBITDA valuation on GURU.Markets provides insight into the extent to which the market is overvaluing the company's protected technological base.
